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Abstract 
 
The human papillomavirus (HPV) vaccines hold great promise for preventing several cancers 
caused by HPV infections. Yet, little attention has been given to whether HPV could respond 
evolutionarily to the new selection pressures imposed on it by the novel immunity response 
created by the vaccine. Here, we present and theoretically validate a mechanism by which the 
vaccine alters the Transmission-Recovery trade-off that constrains HPV’s virulence such that 
higher oncogene expression is favoured. With a high oncogene expression strategy the virus is 
able to increase its viral load and infected cell population before clearance by the vaccine, thus 
improving its chances of transmission. This new rapid cell-proliferation strategy is able to 
circulate between hosts with medium-to-high turnover rates of sexual partners. We also discuss 
the importance of better quantifying the duration of challenge infections and the degree to which 
a vaccinated host can shed virus. The generality of the models presented here suggests a wider 
applicability of this mechanism and thus, highlights the need to investigate viral oncogenicity 
from an evolutionary perspective. 
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 Introduction 1 
 2 
There is considerable excitement surrounding the Human papillomavirus (HPV) vaccines 3 
due to their innovative virus-like-particles (VLP) technology and the very high efficacy rates 4 
found in clinical trials 
1,2
. The HPV vaccine is hailed as a very effective preventative measure 5 
against the several cancers (cervical, penile, anal, head-and-neck) that are caused by this very 6 
common sexually transmitted virus. Since HPV is a double-stranded DNA (dsDNA) virus, it is 7 
often argued that it is unlikely that escape mutants could evolve to evade the VLP-induced 8 
immunity against the virus’s L1 surface protein, as is common in RNA virus evolution 2,3.  9 
Lacking in these discussions of potential HPV vaccination response (vaccine escape or type 10 
replacement) is the idea that viruses can respond to vaccines by increasing their virulence 
4,5
. An 11 
important example of which to note is the vaccine-induced evolution of Marek’s Disease virus 12 
(MDV), which is also a dsDNA oncovirus. Unexpectedly, MDV has evolved increased virulence 13 
and escape mutants in response to several vaccination campaigns 
6,7
. Here, we heed this 14 
cautionary tale and are the first to investigate the potential of HPV to evolve higher virulence in 15 
response to the vaccine immunity. 16 
In many infections, the within-host density of the infectious agent is the appropriate 17 
measure of virulence. For example, Antia et al. define a lethal quantity of a parasite as a natural 18 
choice for the maximal level of virulence and they show that within-host dynamics select for a 19 
quantity that is just below lethal 
8
. However, HPV is mostly avirulent and asymptomatic and is 20 
carried at low within-host densities. Only after several years of persistence do HPV infections 21 
become deadly by the transformation of host cells that have become malignant after the infection 22 
has stopped being productive for the virus 
9,10
. Thus, the classic definition of virulence as a 23 
consequence of high nearly lethal parasite dose as a strategy that benefits the virus does not 24 
readily apply to natural HPV infections.  25 
Defining HPV’s virulence requires understanding the selection pressures that shape less 26 
virulent pathogens, and specifically, oncoviruses. HPV exists as dozens of different types (i.e. 27 
strains) with differing pathologies; the most clinically relevant being the high-risk (HR) types 28 
which have oncogenes (E5, E6, E7) that interfere with the cell’s growth cycle11. Despite the 29 
cancer-centric name, the main function of the oncogenes is to stimulate cell cycle re-entry in the 30 
mid-epithelial layers in order to allow genome amplification 
11
. As a result, the virus cannot31 
replicate without the oncogenes. There are two main additional beneficial functions of these 32 
genes in HR types. First, the oncogenes interfere with the innate immune system (e.g. inhibition 33 
of interferon synthesis and receptor signaling 
11,12
), thus delaying the activation of the adaptive 34 
immune response
13
. Second, the oncogenes inactivate the host’s cell cycle regulators (proteins 35 
p53 and pPB) in order to stimulate cell proliferation
14
. This increases the number of infected 36 
cells without having to infect new cells or to increase the intrinsic replication rate of the virus. 37 
Both of these oncogene functions improve the chances of transmission by increasing the duration 38 
of the infection, and by increasing the amount of viruses transmitted per host-to-susceptible 39 
contact. Nevertheless, it has been found that these oncogenes are not expressed at high levels 40 
during acute infections because  the early viral protein E2 suppresses oncogene expression
10,15
. If41 
the oncogenes are very beneficial, then why are they not expressed in higher quantities?  42 
It is believed that the cost of stimulating the growth of a large density of infected cells is 43 
rapid detection by the immune system. Indeed, low-risk (LR) types that create genital warts are 44 
cleared faster than HR types
11,16
 because most HR lesions begin flat and inconspicuous and only45 
with time does the extra cell proliferation they induce becomes noticeable to immune agents
11
.46 
Clearance after immune detection, then, appears to be a major factor affecting HPV’s life 47 
history. Therefore, we and Orlando et al. believe that the main trade-off that affects this virus is 48 
the Transmission-Recovery trade-off
17,18
, and not the classic Transmission-Virulence trade-off49 
that constrains more virulent pathogens
16
 (we are unaware of studies that suggest the contrary).50 
The Transmission-Recovery trade-off posits that host recovery is the main limitation on 51 
pathogen replication because if recovery happens before transmission then the pathogen’s R0 is 52 
less than 1 and it cannot persistently circulate. Generally, the Transmission-Recovery trade-off is 53 
believed to be the main selection pressure constraining less virulent pathogens
17
.54 
Vaccinated hosts are a new environment in which the vaccine-induced immune response 55 
will act as a strong, novel selective pressure. A unique feature of the immunity induced by the 56 
HPV vaccines is that it triggers a large antibody response, one that is at least two orders of 57 
magnitude larger than the natural response
19
. Also distinct from natural immunity is the duration58 
of infection. Vaccine efficacy trials have shown that 99 % of vaccinated hosts clear challenge 59 
infections with targeted types within 6 months
20
. We postulate that since the immune response in60 
 vaccinated hosts will always be triggered by memory cells and will always mount quickly, then 61 
the current “lay low” strategy that HR vaccine-targeted types use to stay longer inside a host 62 
ceases to be effective. We investigated whether altering the Transmission-Recovery trade-off in 63 
vaccinated hosts could drive vaccine-targeted HR types to increase their virulence by changing 64 
their oncogene production. Using an evolutionary ecology modelling approach, we find that, 65 
indeed, higher oncogene expression is favoured in vaccinated hosts, which subsequently 66 
increases the chances of transmission before clearance by the vaccine.  67 
 68 
 69 
 70 
 71 
Methods 72 
We developed a within-host model to represent an HPV infection in an unvaccinated 73 
host, which was then modified to represent a vaccinated host. These models were then linked to 74 
epidemiological functions (similar to 
8,17,21
) because selection pressures happen at both the 75 
within- and between-host levels. Note that parameter estimates for both within- and between-76 
host models were taken from the literature (see Tables 1 and 2). 77 
Within-host models 78 
The population of free virions, V, come into contact with uninfected cells, X, and infect 79 
them at a rate ψ making infected cells, Y1. See the Appendix for the reduction that allows us to 80 
not explicitly include X in the model. The first term of Y1 encapsulates the creation of newly 81 
infected cells by the interaction of uninfected cells with free virions, where N represents the total 82 
population of all epithelial cells and ϕ is a half-growth constant. The infected cells can either 83 
continue their life cycle or they can become self-proliferating cells, Y2. These cells have a higher 84 
expression of the oncogenes, E6 and E7, which drive the cells to divide more in the mid-layer of 85 
the epithelium before terminating and dying. Let ε represent the rate of oncogene expression of 86 
 the HPV type once in an infected cell. The rate of oncogene expression controls the conversion 87 
of Y1 cells into becoming self-proliferating cells Y2.  Self-proliferating infected cells grow at a 88 
rate rε, proportional to their own density, and is dependent on oncogene expression (i.e. the 89 
higher the oncogene expression the more cell division). Both types of infected cells contribute to 90 
the overall population of free virions, V, by differing virion production rates, ki. Since HPV is a 91 
non-lytic virus both kinds of infected cells die at the same rate, μ, and their viral production rates 92 
are adjusted by the infected cell death rate, μ ki. Free virions are cleared at a rate δ and the 93 
antibody response is captured implicitly by this viral clearance rate.  94 
Finally, we assume that the cytotoxic T-cell (CTL) response, Z, is only initiated by the 95 
growth of Y2, and proliferates at a rate ω. The reason for this is two-fold. First, HPV infection is 96 
exclusively intraepithelial which causes no viremia and also hides antigen 
11
, therefore  extra cell 97 
growth is a signal to the immune system that something is wrong 
11,16
. Second, the cell-mediated 98 
response needed for clearance is predominantly against the oncogene E6 
12,13,22
. Note that for 99 
simplicity we assume that the CTL kill both groups of infected cells with equally efficiency, with 100 
the killing rate a. Altogether then the unvaccinated host model is, 101 
 102 
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 104 
It should be noted that we considered a simpler model with only one infected cell population, 105 
and we also considered differential CTL killing rates (see Appendix). 106 
In order to represent vaccinated hosts, several changes were made to this model: (i) The 107 
vaccine causes a strong antibody response, therefore, δ is increased to δvac; (ii) proliferation of 108 
the CTL is now initiated by the vaccine-created memory response, not the innate response, so 109 
 only a very small amount of virus present (in Y1, Y2 or V) will trigger the memory response 110 
targeting L1 epitopes to activate the adaptive response to invade, thus this changes the Z equation 111 
and Z's initial conditions; (iii) the antibodies that flood the infection site help prevent newly 112 
produced free virions from infecting new cells, thus δvac scales down the infection rate of new 113 
cells, ψ. Together, this gives the model for a vaccinated host, 114 
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where, now Z0 is set to a value that initiates the Z equation once the infection is started. This is 116 
equivalent to having a very low threshold, such that a very small amount of the virus triggers the 117 
response, which is equivalent to being triggered by the mere presence of the virus, and not viral 118 
growth dependent as it is in the unvaccinated host (see ‘auto-pilot’ immune response 23 and refs 119 
therein). The CTL in a vaccinated host proliferate at a higher rate, ωvac. 120 
 121 
Within-host viral fitness 122 
Viral load is a measure of the virus’ reproductive output inside a particular host 123 
environment. The total amount of virus it is able to produce during the course of the infection 124 
represents the fitness of the virus for that particular within-host environment. We are interested 125 
to see how oncogene production changes viral output, so we want to determine the optimal 126 
oncogene strategy, ε*, which is defined as the oncogene expression that maximizes the total viral 127 
output of a host. To determine this we first find the total viral output, VTotal, of a host 
24
, by 128 
finding the integral of the viral load curve, V,   129 
0
( ) ( , )TotalV V t dt 

                                                         (3) 130 
 then, we find the maximum with respect to ε, which gives ε*. We can then compare the ε* 131 
selected for in distinct within-host environments (vaccinated vs. unvaccinated). Note that 132 
because the model cannot be solved analytically, equation 4 was computed numerically, which is 133 
also true for the equations that follow. The maxima were computed numerically using the 134 
function NMaximize in Mathematica. 135 
 136 
Transmission and between-host fitness 137 
Next we consider the effects of transmission. An optimal strategy at the within-host level 138 
might not be optimal for between-host transmission 
25
. We consider, then, how linking these 139 
within-host models to  a different transmission function that represent the relationship between 140 
viral load and transmission (similar to 
8,21
). We considered a linear but scaled down rate of 141 
transmission, where α is 0 < α < 1. 142 
 
 
                                                         ( )V V                                                               (4)  
Since HPV is for the most part avirulent (virus produces almost no mortality), we equate 143 
the reproductive number, R0, to the number of new infections caused by an infected host before 144 
clearing the virions (similar to 
24
). To find an expression for R0 we consider an equation that 145 
represents the number of hosts infected by the focal infected individual, 146 
                                   ( ) ( ) ( ) ( )I t dt I t mg t t dt                                               (5) 147 
where m is the rate of sexual acts, g(t) is the probability that the partner is susceptible, given a 148 
sex act, and β(t) is the probability of transmission given a sex act with a susceptible partner. 149 
From this equation we get an expression for the total number of infected hosts an individual can 150 
cause, such that  151 
                                      0
0
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
                                           (6) 152 
We include ε since we are interested in how oncogene expression can affect the R0 of the 153 
infected host. It is important to consider g(t) because humans are fairly monogamous, so 154 
 transmission to a new host happens only after switching to a new sexual partner, the chance of 155 
which goes up in time. This changes the value of each contact event putting more weight on later 156 
sexual contacts. Thus the state of partnership affects transmission of a sexually transmitted 157 
pathogen like HPV. We modeled g(t) explicitly using a model of three different states that the 158 
infected individual can be in with respect to sexual partnerships, 159 
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where ρ is the rate of new partner acquisition and σ is the rate of partner break up. Here g(t) is 161 
the probability the individual is in a partnership with a susceptible, s(t) is the probability of them 162 
being single, and b(t) is the probability that their partner is also infected. Note that a host can 163 
only be in one of these states and thus at any given time g(t) + s(t) + b(t) = 1. The initial 164 
conditions were { , , } {1,0,0}b s g  .The focal host, then, begins by being in a partnership with the 165 
host who gave them the infection, and then, we assume that they become single before forming a 166 
new partnership, b → s. We assume that the host does not form partnerships with hosts that have 167 
the same infection. At rate m β(t)g the focal host infects their new partner and they, again, are in 168 
a partnership with an infected host, g → b. An analytic solution for g(t) is not easily found 169 
because g  is non-autonomous and so g(t) was calculated numerically. 170 
 171 
Host Heterogeneity:  Immune status 172 
HPV vaccine efficacy in immunocompetent patients is very high, where most vaccinated 173 
individuals clear challenge infections within 6 months 
26
. The effect of the HPV vaccine in 174 
immunocompromised patients should be diminished and overall, the strength of the immune 175 
response will vary among individuals. It is believed that immunocompromised patients can build 176 
a vaccine-induced humoral response because the HPV VLPs used in the vaccine are highly 177 
immunogenic 
27
. For instance, HIV-positive men without low CD4+ counts have shown to 178 
successfully seroconvert after vaccination 
28
 though at lower titres than HIV-negative patients 179 
29,30
. Immunocompromised individuals with low CD4+ counts or B-cell deficiencies will have 180 
 trouble building the adaptive response needed to clear the HPV infection and so, at the very least, 181 
vaccinated immunocompromised patients should clear a challenge HPV infection slower than 182 
vaccinated immunocompetent patients. Unfortunately, HPV vaccine efficacy and immunological 183 
studies in immunocompromised patients are few 
29
. Here, we considered how impairment to the 184 
adaptive response affects the results by investigating results when CTL proliferations rates, ω, 185 
and the initial densities of CTL were one order of magnitude lower the parameter estimate and 186 
initial conditions of the natural case considered.   187 
 188 
Host Heterogeneity:  Sexual behaviour 189 
Sexual behaviour varies between hosts and with age. The host’s sexual partnership 190 
switching behaviour is important to the transmission of the virus. Hosts that are celibate or do 191 
not change sexual partners within the duration of the infection are “dead ends” for the virus, 192 
signifying that the R0 of that individual is less than 1 and, thus, only the formation of a new 193 
partnership can lead to transmission 
31
.  We classified  sexual behaviours into four groups (see 194 
Table 1): ‘long partnerships’ to represent individuals who are in long-term serial monogamous 195 
relationships; ‘short partnerships’ on average have 2 to 5 partners per year; ‘casual relationships’ 196 
have even higher partner turnover; and ‘superspreaders’, such as sex workers, who have 20+ 197 
partners per year. Partner acquisition, break-up, and  sex act rates were obtained from the 198 
literature for these groups and all these rates increase with increased partnership turnover (Table 199 
1). Also note that the per-partnership transmission probability is 0.6 for HPV 
32
, and its R0 is 2, 200 
though higher for core-group individuals (e.g. superspreaders) 
33
. 201 
 202 
 203 
 204 
 205 
 206 
 207 
 Results 208 
Unvaccinated host results 209 
The viral-immunity dynamics were represented using a within-host model. For various 210 
values of oncogene expression, the unvaccinated model shows that CTL invasion is triggered if 211 
the virus drives many infected cells to divide quickly, thus shortening the duration of the 212 
infection (Fig. 1). The model, then, captures the recovery constraint that we expect. The amount 213 
of oncogene expression that is favoured under this constraint is the one that generates the 214 
maximal viral output within the duration of the infection (maximum of Vtotal, equation 4). For an 215 
infection of 1.5 years (HPV-16 is cleared between 0.5 - 4.9 years
34
 and on average before two 216 
years) we find that the optimal oncogene expression, ε*, is below 0.2 (Fig. 3 a). This model, thus, 217 
depicts the HR HPV type strategy of producing few extra self-dividing infected cells in order to 218 
have lesions that are fairly flat on the surface during acute infections
16
.   219 
After calibrating the free parameter α to be 6 x 10-6 such that the short partnership group 220 
had an R0 of 2 
33
, we then estimated the R0 of the other sexual behaviour groups. The R0 was 2.9 221 
for the casual group, < 1 for the long partnership group and 9.3 for superspreaders (Fig. 3b), 222 
which is realistic though a bit low considering the high partnership turnover rates of 223 
superspreaders.   224 
 225 
Vaccinated host results 226 
Unlike the unvaccinated host, the vaccinated within-host environment does not select for 227 
low oncogene expression. Instead, oncogene expression can be very high since the total viral 228 
load, Vtotal, grows monotonically with higher ε values (Fig. 3c), suggesting that the cost of growth 229 
via cell division is removed in vaccinated hosts. For strains with low oncogene expression 230 
strategies, the total viral output is sufficiently low that the vaccine is able to clear them 231 
effectively (see Fig. 2 where Y1, Y2 and V decay to zero for ε values below 0.7); suggesting then 232 
that a high antibody response is an effective method to decrease viral replication. However, for 233 
higher ε, this no longer holds and the exponential growth of Vtotal (ε > 0.7; Fig. 3c) can be 234 
explained by Figure 2 where the Y1, Y2 and V curves grow before clearance. Therefore, higher ε-235 
 driven growth allows the virus to produce a high viral load before the inevitable clearance by the 236 
vaccine. Note also that vaccinated immunodeficient hosts with high ε (ε > 0.5) produce higher 237 
viral loads than vaccinated immunocompetent hosts with the same ε (Fig. 3c).  As another 238 
measure of virulence, comparing the populations of Y2 cells shows that vaccinated hosts have 239 
less Y2 cells than the unvaccinated host for ε < 0.9, however, for ε > 0.9 the Y2 populations in 240 
vaccinated hosts reach a higher peak (compare Y2 curves in Fig. 1 and Fig. 2). 241 
 We determined the between-host fitness of the higher ε strategies by checking that the 242 
viral loads are high enough for transmission within a population (equation 6). Since there is no 243 
longer a maximum in the vaccinated host that defines the optimal oncogene expression, we 244 
instead determine where R0 = 1 and define εvac* as the oncogene expression necessary for a strain 245 
to persist in a population (Fig. 3d).  We find that the R0 (ε) curve of the long partnership group 246 
does not reach R0 =1 within any reasonable ε value; implying that even with very high viral 247 
loads, there is not enough partner-switching to allow for transmission within the infection 248 
window. The other three groups (short, casual and superspreaders) do reach R0 = 1 when ε = 3.3, 249 
1.6, and 1.3 respectively (Fig. 3d). We find that the shape of the vaccinated R0 (ε) curve rose for 250 
higher values of ε, which is not possible in unvaccinated hosts because of the Transmission-251 
Recovery trade-off (compare Fig. 3 b and d). This implies that removing the ability of the virus 252 
to delay effector cell invasion allows types with higher oncogene expression to have R0 values 253 
higher than 1, and thus can spread in the population. Consequently, the vaccine lifts the 254 
constraint that is most likely keeping HPV virulence low. Finally, comparing Figure 3a and c, 255 
this shows that in vaccinated immunocompetent superspreaders this new ε-strategy requires a 256 
lower minimum viral load, of < 10
7
, for persistent transmission.   257 
Since the vaccine’s main response is humoral, we considered how increasing the strength 258 
of the antibody response affected εvac*. In Figure 4a, we see that as δvac is increased to 100 times 259 
the natural antibody clearance rate, a higher εvac* is needed for a strain to persist. Thus, the 260 
vaccine response selects for high oncogene expression. The strains in the shaded regions that are 261 
above all three curves have ε-values above εvac* and could out-compete strains with lower εvac* 262 
because they can circulate in all three kinds of hosts (Fig. 4a). In Figure 4b, we plotted the 263 
derivative at εvac* for different strengths of the humoral response (for increasing δvac) as a 264 
measure of the strength of the selection for εvac*. Selection for εvac* is faster when the humoral 265 
 response is weaker (δvac < 1) and it is also faster in immunodeficient hosts (Fig. 4b), suggesting 266 
that immunodeficient patients provide a better environment for the emergence of more virulent 267 
strains. 268 
Note that the long partnership group is not included in the analysis in Figure 4 because 269 
this group does not reach R0 = 1 (as explained above). This implies that hosts engaged in longer 270 
partnerships and who have contracted a challenge infection lasting up to 150 days have R0 < 1. 271 
These hosts, then, do not contribute to the persistent circulation of strains with higher oncogene 272 
expression.  273 
Finally, Figure 4c shows how the duration of infection in a vaccinated host affects the 274 
εvac*. High initial Z values, Z0, equates to faster invasion by the adaptive response. As the 275 
duration of the infection shrinks due to the faster clearance by CTL, a higher εvac* is needed for 276 
persistence. Note, however, that if the CTL-invasion happens within less than 50 days (Z0 > 1), 277 
then the vaccine is able to clear all infections in all groups, regardless of the level of oncogene 278 
expression.  279 
 280 
 281 
 282 
Discussion 283 
The evolutionary responses of viruses to vaccines are of serious concern, and they may 284 
appear several years after the introduction of such control measures
35
. In a review, Read and 285 
Mackinnon contrast successful vaccines that stimulated natural immunity to novel vaccines 286 
which stimulate new responses that differ considerably from natural immunity. They warn that 287 
imposing new effector mechanisms can create very different selection pressures, with potentially 288 
unwanted consequences
5
. Our findings appear to coincide with this scenario, in that the novel 289 
vaccine immunity favours increased virulence in order to allow for transmission during the short 290 
window of time before vaccine-induced clearance. 291 
 The HPV vaccines change the within-host ecology encountered by the virus in three main 292 
ways. First, the vaccine-targeted types experience a strong antibody response that is unnaturally 293 
high
30
, and which we find drives the oncogene expression necessary for persistent circulation up 294 
further. Second, the vaccine-induced effector cells invade faster, and invasion can no longer be 295 
delayed through strategies using slow viral replication and signalling interference. We show that 296 
this effect changes the Transmission-Recovery trade-off such that low oncogene expression 297 
strategies are no longer favoured. 298 
Finally, the vaccine adaptive response now exclusively targets epitopes of the surface 299 
protein L1
30
, which is distinct from natural responses that target the early proteins, E2, E6 and 300 
E7, for clearance
13,22
. Since the L1 is a late gene whose epitopes are expressed in the upper 301 
layers of epithelium or are exposed on the capsids
11
, the vaccine-induced effectors will mainly 302 
target free virions and these terminating cells. However, infected cells of the mid- and lower-303 
levels of the epithelium express the early proteins, and so should be targeted less readily by the 304 
vaccine response. Though this detail is not present in our models, we expect that it could 305 
augment the effect we found, by selecting against the re-infection strategy and favouring the self-306 
proliferation strategy. In this new environment, variants of the vaccine-targeted types exhibiting 307 
higher than average cell proliferation would have an advantage.  308 
Discussions of HPV evolutionary responses have been scant and have focused on the 309 
potential of L1 neutralization escape
36
. We believe that we are the first to suggest this kind of 310 
evolutionary response in HPV types targeted by (or cross-reactive with) the vaccine. The main 311 
form of vaccine “leakiness” that has been addressed in the HPV literature is that of type-312 
specificity and whether it can result in type replacement 
37,38
. A “leak” that has not been 313 
considered, and what we find here to be important, is what happens when the vaccine does not 314 
block infection and viral shedding? Given that challenge infections by vaccine-targeted types 315 
were detectable in vaccinated women
26
 during HPV vaccine trials, we argue that the vaccine 316 
does not always fully block viral shedding. Indeed, a humoral response may not always provide 317 
perfect protection from viral challenge
39
. Since HPV is transmitted mechanically through the 318 
shedding of both free virions and dead infected keratinocytes from the epithelial surface
40
, it is 319 
possible then, that  even if the antibody response lowers the free virion population significantly, 320 
a vaccinated host could still transmit the virus by shedding infected keratinocytes. For 321 
 comparison, consider once again the oncogenic MDV example in which shedding of epithelial 322 
cells was also involved in transmission. Indeed, the MDV vaccines are leaky because they do not 323 
block infection and viral shedding (though this leak is more pronounced compared to the HPV 324 
vaccine’s stronger prophylactic effect), which has played an important role in the subsequent 325 
virulence evolution of MDV
6,7
. In light of this, we strongly encourage studies of challenge 326 
infections in vaccinated hosts, their frequency, their duration, and  to what degree they shed 327 
infected cells. Cross-sectional epidemiological studies or longitudinal time-points separated 6 328 
months apart will often lack the resolution to address these questions, especially if the challenges 329 
are short lived. 330 
Our model assumes that the high antibody response is instantaneous (δvac is a constant), 331 
and thus it captures the prophylactic effect of high neutralizing antibody titres the vaccine is 332 
intended to create. Locally, however, there should be lower levels of neutralizing antibodies (e.g. 333 
in cervicovaginal secretions)
13
 and there should be a lag from the time of first challenge until the 334 
time the memory B cell induced antibodies, and subsequent cellular response, invade at full 335 
force. We have not seen empirical estimates of how many days this takes, though their timing 336 
could have considerable consequences on the evolution of the virus and its transmission.  337 
To demonstrate the essential ingredients of the phenomenon, our conceptual model had to 338 
idealize the viral replication process by neglecting many of its known details. So, though we 339 
demonstrate that virulence evolution is possible, we cannot determine with this study whether it 340 
is probable. It has been argued that accelerated carcinogenesis is not adaptive because cells in 341 
higher grade lesions do not produce fully assembled virions
41
. However, given that animal 342 
models can be infected with DNA plasmids to produce robust, productive infections
42,43
, then, 343 
how  infectious are keratinocytes containing HPV DNA? Even if cancer cells themselves are not 344 
infectious, how infectious are the cells in the lesions leading up to cancer? Experiments, then, are 345 
needed to assess to what degree oncogene expression can rise while maintaining viable viral 346 
production, infectiousness and transmission.  Furthermore, following several challenges to the 347 
prevailing view of slow dsDNA virus evolution (where mechanisms such as recombination are 348 
possible
44–48
), there is a need for more direct investigations into the evolutionary potential of 349 
HPV variants.  350 
 In a recent study, Orlando et al. found that HR types are best suited for transmission in 351 
long partnerships (because HR infections last longer) while shorter partnerships with higher 352 
turnover rates  allow for the persistence of  LR types (because LR types are cleared faster) 
16
. We 353 
show here that by artificially shortening the infection duration, targeted HR types can more 354 
strongly adopt the strategy of cell proliferation (a strategy that was costly in natural conditions) 355 
in order to increase their chance of transmission, thus, adopting a similar strategy to LR types. 356 
Yet, oncogenes of HR types have stronger cell transforming abilities, and expression at higher 357 
levels should more readily cause cellular genetic instabilities and lead to faster progression 358 
towards cancer.  359 
Our study does not contain a full population model of interacting hosts, so we cannot 360 
investigate the conditions needed for a host population to maintain an emergent vaccine-adapted 361 
type. Heterogeneity of hosts plays an important role in the emergence of strains 
49
, and indeed we 362 
found variation in the optimal oncogene expression required of the virus to persist in different 363 
sexual activity groups. For instance, superspreaders required lower viral loads for persistent 364 
transmission, and in a highly sexually active core group this could favour the emergence of a 365 
variant with higher oncogene expression. Emergence happens in stuttering transmission chains, 366 
potentially in small groups of individuals, and certain host groups are more likely to be carriers 367 
and superspreaders
50–52
. Therefore, future studies should consider how pockets of core-group 368 
individuals (the causal and superspreader groups in this study) or of immunodeficient individuals 369 
may contribute to the emergence and circulation of new variants. 370 
In conclusion, the uniqueness of the HPV vaccines lies in that they target a virus that is 371 
avirulent for the majority of hosts but has strong cell transformation properties. Other 372 
oncoviruses have similar features to HPV, making it likely that this vaccination program may be 373 
emulated in the future. Given that virulence is not a fixed trait in any pathogen, it is in our best 374 
interest to understand how we are changing the ecological landscape and the selection pressures 375 
acting on the virus, in order to more confidently declare a vaccine’s evolutionary robustness. 376 
 377 
 378 
 379 
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 Table and Figure Captions 
 
Table 1. Within-host parameter estimates. The vaccine parameters ωvac and δvac were set to be 100 times 
19
 the unvaccinated estimates listed in this table. 
 
Table 2. Sexual behaviour groups and between-host parameters from literature. 
 
Figure 1. Time-series of unvaccinated within-host model for various oncogene expression levels. 
Warm to cool colours represent time-series runs for different ε values from 0 to 1. Lower ε gives 
slower growth of Y1 and Y2 (e.g. orange-red).  Note that Y1 and Y2 infected cells produce the V curves. The 
invasion of Z is delayed at lower levels of ε, thus faster growth of Y2, due to higher ε, leads to faster 
clearance.  
 
Figure 2. Time-series of vaccinated within-host model for various oncogene expression levels. At 
lower levels of oncogene expression the virus is cleared effectively by the CTL (decay of Y1, Y2, and V for 
ε  < 0.7) but if higher, then viral load increases due to an increase in self-dividing infected cells. Note that 
Z appears at the same time regardless of oncogene expression. The range of ε shown is from 0 to 1.2. 
  
Figure 3. Unvaccinated host plots. a) Vtotal of both immunocompetent and -deficient hosts. The ε* 
that is selected for by within-host processes is low, which demonstrates that recovery is the cost to rapid 
growth inside the host. Immunodeficient hosts can select for a slightly higher optimal oncogene 
expression. Unvaccinated immunodeficient parameters: ω = 0.0001, Z0 = 10
-5
. b) R0 with respect to 
oncogene expression for various sexual behaviours. Immunocompetent only. Superspreaders (yellow) 
and individuals with casual partnerships (purple) have higher R0 values (maximum) above the average 
(short partnerships, red), and individuals with long partnerships (blue) are below 1. Including the sexual 
behaviour model does not change the ε* away from the within-host optimal, thus all three groups select 
for the same ε*. Vaccinated host plots. c) Vtotal of both immunocompetent and immunodeficient 
hosts. No maximum is achieved, instead higher oncogene expression allows for higher viral loads. 
Immunodeficient hosts have steeper curves implying they reach higher viral loads with lower ε values. 
Vaccinated immunodeficient parameters: ω = 0.01, Z0 = 10
-5
. d) R0 with respect to oncogene expression 
for various sexual behaviours. Immunocompetent only. The ε values where the curves cross R0 = 1 is 
the minimum value of ε needed for the virus to circulate, εvac*. Superspreaders need a lower oncogene 
expression (εvac*) to maintain circulation of the virus, than casual and short partnerships (higher εvac* on 
purple and red curves respectively). Long partnerships (blue) do not rise fast enough to cross R0 = 1. 
 
Figure 4. Effect of vaccine humoral response on optimal epsilon. Sexual behaviour groups: 
superspreaders (yellow), casual (purple), and short (red). a) The oncogene expression needed for 
persistent circulation, εvac*, with respect to the strength of the antibody response, δvac. Generally, εvac* 
increases with a stronger humoral response. Note that above each line are ε values that can also circulate 
(with R0 values > 1). b) The derivative at εvac* for various δvac . The strength of selection for higher 
epsilon is stronger in immunodeficient hosts (dashed lines) in both casual and superspreader groups. 
Higher δvac implies slower selection towards εvac*. c) The effect of vaccine-induced clearance time on 
optimal epsilon. Each line represents the oncogene expression needed for persistent circulation, εvac*, in a 
particular sex group, thus the shaded region above are ε values that have R0 values higher than 1. The 
oncogene expression needed for εvac* in the vaccinated host depends on how quickly vaccine-induced 
clearance happens. At Z0 = 10
-4
 the vaccinated host sheds virus for about 150 days, and at Z0 = 1 the 
vaccinated host shed the virus for 50 days. For all three sexual behaviour groups, if the challenge 
infection is cleared quickly (high Z0) then a higher εvac* is favoured, but if the infection is cleared in under 
50 days then even high oncogene expression cannot help the virus from escaping the vaccine. 
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 Tables  
 
Parameter  Estimate References 
ψ infection rate of uninfected cells 0.0067 day-1 53 
μ death rate of cells 0.048 day-1 54 
k burst size 1000 virions/cell 54 
ω proliferation rate of CTL 0.001 day-1 55 
a killing rate of CTL 0.01 day-1 56 
δ decay rate of free virions 0.05 day-1 57 
r self-division rate of infected cells 0.1 day-1 fixed 
N total population of available cells 10000 fixed 
ϕ half-growth constant 106 fixed 
 
Table 1. 
 
 
Group 
 
Average 
number of 
partners/year 
 
Rates  
(in days) 
 
References 
 
Comments  
 
Long 
partnerships 
 
 
1 
 
ρ = 0.0027 
σ = 0.0004 
m = 0.356 
 
58,59 
60 
61,62 
 
e.g. marriage/common-law, 
serial monogamy 
 
* partnership lasts 6 years 
 
 
Short 
partnerships 
 
 
2-5 
 
ρ = 0.0096 
σ = 0.05 
m = 0.43 
 
59 median 
63* 
64 
 
e.g. dating 
 
*considered dissolution within 
20 days to 12 weeks 
 
 
Casual 
relationships   
 
6-8 
 
ρ  = 0.019 
σ  = 0.1 
m = 0.43  
 
 
65 median 
60* 
64** 
 
e.g. single, dating, hook-ups 
 
* dissolution within 10 days 
** 3 / week 
 
 
Superspreader 
 
 
20 + 
 
 
ρ = 0.068 
σ = 0.44 
m= 1.44   
 
58  
61* 
66** 
 
 
e.g. sex workers, bathhouse 
frequenters, etc. 
 
* dissolution within 2.3 days 
* estimate 11 /week for 48 
weeks 
 
 
Table 2. 
 
 
 Appendix  
1.1 The unvaccinated model 
The population of uninfected basal epithelial cells that HPV targets are represented by the 
variable X, and they are born at a rate λ(t) and die naturally at rate μ. The population of free 
virions, V, come into contact with uninfected cells, X, and infect them at a rate ψ making 
infected cells, Y1. Infection of new uninfected cells is limited by the fact that most cells are 
hidden under the epithelium and so abrasions are needed in order for HPV virions to reach them. 
For this reason we have slowed down the interaction between V and X by making their 
relationship grow hyperbolically (using a type-II functional response). Thus we assign the 
constant ϕ to be the density of uninfected cells at which the rate of growth of the Y1 population is 
half-maximal. 
These infected cells become self-replicating cells, Y2, depending on the rate of oncogene 
expression, ε. Infected cells, Y1 and Y2, are killed by the CTL response, Z. The full model which 
includes all the assumptions mentioned in the methods is, 
1
1 1 1
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1 2 2 2
1 1 2 2
2
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To reduce this model, we assumed that birth rate of the uninfected cells, λ(t), maintains the total 
population size of epithelial cells at a constant population size of N and 
1( ) 0
d X Y
dt

 , thus X 
can be replaced by X = N - Y1. Thus, the Y1.equation becomes 
                                           1 1
1 1 1
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dt N Y
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                                  (A.2) 
as seen in model 1 in the methods.  
 
 1.2 Simplified model 
We considered a simpler version of this model that only contained one class of infected cells, 
      
(
 
)
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Here, the Y equation grows either by the infection of uninfected cells (first term) or from its own 
self-division (second term). The results of this model were very similar to the one in the text, 
with two main exceptions. The unvaccinated immunity does not select for a low oncogene 
expression (Fig. A1 a) but when connected to the partnership model, the transmission constraints 
select for a low oncogene expression (Fig. A1 b). This shows how within- and between-host 
selection pressures can be at odds, and, in this case, the between-host selection pressure 
determines the optimal strategy. The other main difference is that the vaccinated short 
partnership behavior group requires significantly higher oncogene expression (than the super-
spreaders and causal groups) to allow persistent circulation in this sexual behavior group (Fig. 
A1 d).  
  
Figure A1. Unvaccinated and vaccinated within-host Vtotal (a and c respectively) and unvaccinated and vaccinated 
between-host selection for optimal oncogene expression (b and d respectively). 
 
1.3 Sensitivity to parameter values 
Attack rates 
As an initial simplifying assumption, we considered the CTL attack rates against both Y1 and Y2 
infected cell populations to be equal in strength (where Z removes either Yi at a rate, a). 
However, to study the situation where CD8 T-cells attack the infected cell populations 
differentially, we considered slight alterations of models 1 and 2 such that a in equation dY1/dt 
became a1 and in equation dY2/dt the attack rate specific to Y2 cells become a2. A biological 
reason for the natural immune response to exhibit differential attack rates would be that the 
increased oncogene expression in Y2 were differentially targeted (otherwise, the two infected cell 
groups behave similarly). Indeed, the cell-mediated immune response needs to target E6 epitopes 
for effective clearance [1,2]. In this case, a2 should be larger than a1 because Y2 cells maintain a 
higher oncogene expression. We considered this scenario, and found that even if a2 was 
increased by 3 orders of magnitude (in relation to a1) little changed. For instance, in the time-
series the infected cells and viral load peak lower, a smaller population of CD8 T-cells are 
 needed to clear the infection and that the timing and the shapes of the curves remained the same 
(Fig. A2). Likewise, the ε* values found by Vtotal and R0 do not change compared to the scenario 
where the attack rates are the same (Fig. A3). The same can be said for the case where a1 > a2 
(not shown), though a biological reason for this scenario is not apparent. Since the vaccine-
induced immunity targets the L1 late protein, the two infected cell groups should be targeted at 
the same intensity by effector cells (as we considered in the main text). Nonetheless, we 
considered differential attack rates in vaccinated hosts for completeness. In the time-series, when 
a1 > a2 the Y1 peak for the higher oncogene expression is lowered, while the rest of the curves 
stay almost the same (not shown). When a2 > a1, then all Y1 curves decay and the growth of the 
Y2 nearly instantaneous for higher oncogene expression values, thus the “increase rapid cell 
division before clearance” effect is more pronounced (Fig. A4). In both vaccine cases, less 
effector cells (lower Z) are needed to clear the infection and the Vtotal and R0 give the same ε* as 
when the attack rates are equal.  
 
 
Figure A2. Unvaccinated time-series with a2 >> a1 (a2 = 10 and a1 = 0.01), for various ε values (from 0 to 1).  
 
 
  
Figure A3. Unvaccinated Vtotal with a2 >> a1 (a2 = 10 and a1 = 0.01).  
 
 
 
Figure A4. Vaccinated time-series with a2 >> a1 (a2 = 10 and a1 = 0.01), for various ε values (from 0 to 1.2).  
  
Sexual behaviour parameters 
It should be noted that partnership length and turnover can vary throughout a host’s life. 
Therefore, HPV prevalence in different age groups should be linked to higher proportions of 
short or casual individuals in these age groups which permit more transmission of HPV. The 
average partner turnover at different age demographic groups (e.g. in 20s, 30s, or 40s) is cultural 
(and gender-specific), which might help explain variations in HPV prevalence in the same age 
groups across the world [3]. Indeed, we find that the parameter that most affects the host’s R0 is 
 partnership acquisition, ρ, which demonstrates that increasing the number of new partners (even 
when old partnerships have not broken up) increases the transmission of the virus (e.g. fig. A5).  
 
 
 
Figure A5. Vaccinated hosts: oncogene expression needed for transmission, εvac*, is the point where the curve 
crosses R0 = 1, and is most affected by acquisition of new partners rate, ρ. a) parameters σ = 0.05  and m = 0.43 are 
held constant, and ρ is varied (ρL = 0.0027, ρS = 0.0096, ρC = 0.019, ρSS = 0.068). b) paramters ρ = 0.0096 and m = 
0.43 are held constant and σ is varied (σL = 0.0004, σS = 0.05, σC = 0.1, σSS = 0.44). c) parameters ρ = 0.0096 and σ 
= 0.05 are constant and m is varied (mVL = 0.033, mL = 0.356, mC = 0.43 , mSS = 1.45 ).  
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